Moderna, Inc. (FRA:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
22.51
-0.72 (-3.10%)
May 13, 2025, 3:52 PM CET
-79.60%
Market Cap 8.94B
Revenue (ttm) 2.94B
Net Income (ttm) -3.11B
Shares Out n/a
EPS (ttm) -8.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 421
Average Volume 14,509
Open 22.70
Previous Close 23.23
Day's Range 22.51 - 23.30
52-Week Range 20.18 - 155.50
Beta n/a
RSI 44.69
Earnings Date May 1, 2025

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025

CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Bernstein's 41st Annual Strategic Decisions...

5 days ago - Wallstreet:Online

Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025

CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decision...

5 days ago - Accesswire

New vaccine chief rocks pharmaceutical stocks

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.

6 days ago - CNBC Television

Moderna's combo Covid and flu mRNA shot outperforms current vaccines in large trial

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the results of a phase 3 clinical trial published Wednesday in the Journal of the Ame...

6 days ago - NBC News

Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about MRNA stock here.

12 days ago - Seeking Alpha

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026

Moderna Inc. (NASDAQ: MRNA) reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12) , down from an EPS loss of $(3.07) a year ago. The COVID-19 vaccine maker report...

12 days ago - Benzinga

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026

Moderna Inc.  MRNA reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12), down from an EPS loss of $(3.07) a year ago.

12 days ago - Benzinga

Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript

Moderna, Inc. (NASDAQ:MRNA) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsLavina Talukdar - Senior Vice President, Investor...

12 days ago - Seeking Alpha

Moderna, Inc. 2025 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Moderna, Inc.

12 days ago - Seeking Alpha

Moderna beats Wall Street estimates for first-quarter profit and sales

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine...

12 days ago - Reuters

Moderna Misses Sales Forecasts, But Maintains Full-Year Outlook

Moderna stock could take a hit Thursday after the biotech company reported light sales of its Covid vaccine and RSV vaccine.

12 days ago - Investor's Business Daily

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates

Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52)Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of ...

12 days ago - Wallstreet:Online

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates

Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of...

12 days ago - Accesswire

Preview: Moderna's Earnings

Moderna (NASDAQ: MRNA) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Moderna to report an ea...

13 days ago - Benzinga

Behind the Scenes of Moderna's Latest Options Trends

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna . Looking at options history for Moderna (NASDAQ: MRNA) we detected 13 trades. If we consider the specifics of ea...

18 days ago - Benzinga

33 Stocks That Could Rally 50% or More This Year

Analysts say these S&P 500 stocks have at least 50% price upside over the next year or so.

22 days ago - Kiplinger